• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Covance Reports 23% Earnings Growth in 2Q

Covance Reports 23% Earnings Growth in 2Q

July 31, 2008
CenterWatch Staff

Covance reported after the bell Wednesday that its second quarter earnings jumped 22.7% to 79 cents per diluted share compared with the second quarter of 2007. The contract research organization said the earnings excluded one cent per share gain from the sale of its centralized ECG business in 2007.

"In the second quarter Covance continued to capitalize on favorable market dynamics and delivered a strong, broad-based financial performance, including net revenue growth of 14.6% and record operating margin of 15.4%," said Joe Herring, chairman and chief executive officer of Covance.

The company said its backlog surpassed $3 billion. In early trading Thursday, Covance’s shares were up 1.3% to $89.78.

"Early Development revenues grew 5.5% sequentially and operating margins increased 40 basis points from last quarter to 25.4% as new toxicology space started coming online and several phase I projects that were delayed out of the first quarter were initiated,” Herring said. “ In Late-Stage Development, central laboratory and clinical development drove robust segment results, including year-over-year revenue growth of 17.8% and exceptional operating margins of 19.2%.”

The company's Early Development segment includes preclinical toxicology, analytical chemistry, clinical pharmacology services, and research products. Early Development net revenues for the second quarter grew 11.5% year-over-year to $213.1 million, compared with $191.1 million in the second quarter of 2007 and $202.0 million last quarter. Year-over-year revenue growth was led by toxicology and chemistry services. The strong sequential growth of 5.5% was driven by an increase in study starts in clinical pharmacology and the addition of new capacity in North America toxicology.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing